HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Confidentiality For Proprietary Information Drives FDA Plan To Generate More CBD Safety Data

Executive Summary

In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."

You may also be interested in...



US FDA’s Stance On CBD In Cosmetics Hasn’t Changed, And Neither Have Marketing Challenges

The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.

US House Appropriators Keep A Bullseye On FDA’s CBD Regulation Development

Appropriations subcommittee notes the funding in summary of its draft budget bill. Language on FDA’s development of CBD regulatory framework will be included in panel’s report to be released 24 hours before full committee’s markup.

‘Time Is Now’ For FDA Rule On Lawful CBD Use In Supplements, CRN Says In Citizen Petition

The trade group’s petition is second on a regulation for CBD’s use in non-drug products submitted to FDA and largely tracks with CHPA’s November 2019 petition. Comments continue to reach the FDA after in March it reopened its docket about establishing a CBD regulation, but with little data the agency says is needed for its decision.

Related Content

Topics

UsernamePublicRestriction

Register

RS149762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel